Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.

The New England journal of medicine·2026

Same author

[How will artificial intelligence improve cardiovascular prevention?]

Revue medicale suisse·2026

Same author

[Screening for albuminuria to assess cardiovascular risk].

Revue medicale suisse·2026

Same author

Treatment of infected endografts after thoracic endovascular aortic repair: a systematic review.

Science progress·2026

Same author

Sirolimus-Eluting Resorbable Magnesium Scaffold for the Treatment of Patients With Infrapopliteal Arteries Disease: Three-Year Results.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2025

Same author

The BEnefit of LONGitudinal Micro-Incisions Prior to Paclitaxel-Coated Balloon Angioplasty (BELONG Study) in Patients With Lower Extremity Arterial Disease: Clinical Outcomes at 12 Months.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2025

Search research articles

Related Experiment Video

Updated: May 24, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Artificial muscle for end-stage heart failure.

Piergiorgio Tozzi¹, Alexandre Michalis, Daniel Hayoz

¹Department of Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Piergiorgio.Tozzi@chuv.ch

ASAIO Journal (American Society for Artificial Internal Organs : 1992)

|February 29, 2012

Summary

A novel artificial muscle device using Biometal muscle (BM) offers a new treatment for end-stage heart failure. This innovative heart assist device shows promise in improving cardiac function and potentially replacing natural muscle mechanics.

More Related Videos

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Experiment Videos

Last Updated: May 24, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Area of Science:

Biomedical Engineering
Cardiovascular Research
Materials Science

Background:

End-stage heart failure necessitates advanced mechanical circulatory support.
Current heart assist devices have limitations.
Artificial muscle technology presents a novel therapeutic avenue.

Purpose of the Study:

To describe a new artificial muscle device for end-stage heart failure treatment.
To evaluate the efficacy of this device as an alternative to existing heart assist technologies.
To introduce Biometal muscle (BM) as a key component for cardiac assistance.

Main Methods:

Development of a device utilizing a Biometal muscle (BM) matrix of nitinol wires and aramidic fibers.
Integration of the BM with a carbon fiber scaffold for heart tightening and biventricular assistance.
Control of BM contraction via a pacemaker-like microprocessor.
Testing in a dedicated bench model simulating a diseased heart.

Main Results:

The device generated a systolic pressure of 75 mm Hg.
Maximum ejection was 330 ml/min, with an ejection fraction of 12%.
The device operated with a low power requirement (6 V, 250 mA).

Conclusions:

The Biometal muscle device demonstrates potential as an effective heart assist technology.
This innovation could lead to integrating or replacing the mechanical function of natural heart muscles.
Further research may establish this as a new era in treating heart failure.